Abstracts tagged "biomarkers and interferons"

Abstract Number: 11 • 2019 ACR/ARP Annual Meeting
Biomarker Changes for Patients with Rheumatoid Arthritis Receiving Tofacitinib with Methotrexate or Glucocorticoids vs Tofacitinib Monotherapy
Julie Lee¹, Xing Chen ¹, Weidong Zhang ¹, David Martin ¹, Craig Hyde ¹, Tomohiro Hirose ², Shweta Shah ³ and Lori Fitz ¹, ¹Pfizer Inc, Cambridge, MA, ²Pfizer Japan Inc, Toyko, Japan, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Herpes zoster (HZ) is more common in patients (pts) with RA vs…
Abstract Number: 873 • 2017 ACR/ARHP Annual Meeting
Type I High-IFN Gene Signature in Associated with Higher Essdai at Enrollmment and Follow-up in the Prospective Multicenter Assess Cohort of 395 Patients
Jacques-Eric Gottenberg¹, Pierre-Etienne BOST², Benno Schwikowski², Raphaele Seror³, Valérie Devauchelle-Pensec⁴, Philippe Dieudé⁵, Jean-Jacques Dubost⁶, Anne Laure Fauchais⁷, Vincent Goeb⁸, Eric Hachulla⁹, Pierre Yves Hatron¹⁰, Claire Larroche¹¹, Véronique Le-Guern¹², Jacques Morel¹³, Aleth Perdriger¹⁴, Emmanuelle Dernis¹⁵, Stephanie Rist Bouillon¹⁶, Alain Saraux¹⁷, Damien Sène¹⁸, Jean Sibilia¹⁹, Olivier Vittecoq²⁰, Gaetane Nocturne²¹, Sarah TUBIANA²², Philippe Ravaud²³ and Xavier Mariette²⁴, ¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Pasteur Institute, System biologique, PARIS, France, ³Department of Rheumatology, Assistance Publique–Hopitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin Bicêtre, France, ⁴Department of Rheumatology, Brest University Hospital, Brest, France, ⁵Rheumatology, Hôpital Bichat, Paris, France, ⁶Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁷Rheumatology, Limoges, France, ⁸Rheumatologie, Rheumatology Department CHU Teaching Hospital Amiens, Amiens, France, ⁹CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, Lille, France, ¹⁰Internal Medicine, Lille, France, ¹¹Internal Medicine, Paris, France, ¹²service de médecine interne, Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ¹³Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, ¹⁴Service de Rhumatologie, CHRU de Rennes, Rennes, France, ¹⁵Service de Rhumatologie, CH du Mans, Le Mans, France, ¹⁶Rhumatologie, Hopital La Source, La Source, France, ¹⁷Rheumatology, Brest University Hospital, Brest, France, ¹⁸Department of Internal Medicine, Pitié-Salpêtrière Hospital, Paris, France, ¹⁹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²⁰INSERM U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen, France, ²¹INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, Le Kremlin Bicêtre, France, ²²CRB Bichat, PARIS, France, ²³Hôpital Hôtel Dieu, Paris, France, ²⁴Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France
Background/Purpose: The type I interferon (IFN) signature is a hallmark of the pathogenesis of primary Sjögren’s syndrome (pSS). However, little is known regarding the clinical…
Abstract Number: 1369 • 2017 ACR/ARHP Annual Meeting
Interferon Gamma Signature Genes and CXCL10 As New Biomarkers in Early Stage of Rheumatoid Arthritis
Kijun Lee¹, Jennifer Lee², Hong-Ki Min¹, Hae-Rim Kim³, Sang-Heon Lee⁴, Sung-Hwan Park⁵, Ji Hyeon Ju⁶ and Hoyoun Kim¹, ¹The Catholic University of Korea, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South), ³Konkuk University Medical Center, Seoul, Korea, Republic of (South), ⁴Konkuk University School of Medicine, Seoul, Korea, Republic of (South), ⁵Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South), ⁶Division of Rheumatology, Department of Internal Medicine,, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)
Background/Purpose: The purpose of this study is to explore new biomarkers for early diagnosis of rheumatoid arthritis (RA). For better discrimination power, we especially investigated…
Abstract Number: 1083 • 2016 ACR/ARHP Annual Meeting
Discovery and Subsequent Diagnostic Verification of Autoantibodies Against the Major Vault Protein (MVP) in Systemic Lupus Erythematosus
Petra Budde¹, Johannes Schulte-Pelkum¹, Daniel Wirtz¹, Hans-Dieter Zucht¹, Heike Göhler¹, Stefan Vordenbäumen², Peter Schulz-Knappe¹ and Matthias Schneider³, ¹Protagen AG, Dortmund, Germany, ²Rheumatology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany, ³Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany
Background/Purpose: In systemic lupus erythematosus (SLE), early diagnosis and prognostic stratification are still great challenges. The broad characterization of the autoantibody repertoire in SLE is…
Abstract Number: 1217 • 2016 ACR/ARHP Annual Meeting
Identification of Sjogren’s Syndrome-Associated Long Non-Coding RNAs That Are Co-Expressed with Key Protein-Coding Transcripts Involved in Dysregulated Interferon Responses
John A. Ice¹, Indra Adrianto¹, Michelle L. Joachims², Jennifer A. Kelly², Graham B. Wiley¹, Astrid Rasmussen¹, Kiely Grundahl³, Glen D. Houston⁴, David M. Lewis⁴, Lida Radfar⁵, Donald U. Stone^6,7, Joel M. Guthridge², Barbara M. Segal⁸, Nelson L. Rhodus⁹, James Chodosh^10,11, Raj Gopalakrishnan¹², Andrew J.W. Huang¹³, Pamela J Hughes¹⁴, Michael D. Rohrer¹⁵, Judith A. James^16,17,18, Courtney G. Montgomery¹, R. Hal Scofield^1,18,19, Patrick Gaffney¹, Kathy L. Sivils^2,16 and Christopher J. Lessard^1,16, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Department of Oral and Maxillofacial Pathology, University of Oklahoma College of Dentistry, Oklahoma City, OK, ⁵Oral Diagnosis and Radiology Department, University of Oklahoma College of Dentistry, Oklahoma City, OK, ⁶King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia, ⁷Department of Ophthalmology, Johns Hopkins University, Baltimore, MD, ⁸Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ⁹Department of Diagnostic and Biological Sciences, University of Minnesota School of Dentistry, Minneapolis, MN, ¹⁰Harvard Medical School, Boston, MA, ¹¹Massachusetts Eye and Ear Infirmary, Boston, MA, ¹²Diagnostic and Biological Sciences, Division of Oral Pathology, University of Minnesota School of Dentistry, Minneapolis, MN, ¹³Department of Ophthalmology and Visual Sciences, Washington University, St. Louis, MO, ¹⁴Department of Oral and Maxillofacial Surgery, Oregon Health & Science University School of Dentistry, Portland, OR, ¹⁵Hard Tissue Research Laboratory, University of Minnesota School of Dentistry, Minneapolis, MN, ¹⁶Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁷Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁸Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁹US Department of Veterans Affairs Medical Center, Oklahoma City, OK
Background/Purpose: The “interferon signature”, marked by transcriptional upregulation of interferon (IFN)-inducible (IFI) genes, is a common finding in Sjögren’s syndrome (SS) that is associated with…
Abstract Number: 762 • 2015 ACR/ARHP Annual Meeting
The Interferon Signature Correlates with Longitudinal Disease Severity in Systemic Lupus Erythematosus, but Adds Little to Conventional Prognostic Indicators
Arundip Asaduzzaman¹, Babak Noamani², Denisse Bonilla³, Dafna Gladman⁴, Murray Urowitz^5,6, Paul R. Fortin⁷, Carolina Landolt-Marticorena⁸ and Joan E. Wither⁹, ¹Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²Genetics and developmental biology, University Health Network, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁷Université Laval, CHU de Québec, Québec, QC, Canada, ⁸1E420/Div of Rheumatology, University Health Network, Toronto, ON, Canada, ⁹Rheumatology, University Health Network, Toronto, ON, Canada
Background/Purpose: Type I interferon (IFN) is thought to play an important part in the pathophysiology of systemic lupus erythematosus (SLE), and cross-sectional data suggests an…
Abstract Number: 2929 • 2014 ACR/ARHP Annual Meeting
Molecular Diagnostics for Patient Subsetting in Sjögren’s Syndrome
John C. Hall¹, Alan N. Baer¹, Mi Y. Lam², Lindsey A. Criswell³, Antony Rosen¹ and Livia Casciola Rosen¹, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Orofacial Sciences, University of California San Francisco, San Francisco, CA, ³Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA
Background/Purpose Sjögren’s syndrome (SS) is a chronic autoimmune disease which targets exocrine glands, particularly salivary and lacrimal glands. While all SS patients have abnormal secretory…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].